tbuckley/cabot-search huggingface dataset:
Developing an optimal stratification model for colorectal cancer screening and reducing racial disparities in multi-center population-based studies
Authors: Jianbo Tian, Ming Zhang, Fuwei Zhang, Kai Gao, Zequn Lu, Yimin Cai, Can Chen, Caibo Ning, Yanmin Li, Sangni Qian, Hao Bai, Yizhuo Liu, Heng Zhang, Shuoni Chen, Xiangpan Li, Yongchang Wei, Bin Li, Ying Zhu, Jinhua Yang, Mingjuan Jin, Xiaoping Miao, Kun Chen
Journal: Genome Medicine (2024)

Abstract Background Early detection of colorectal neoplasms can reduce the colorectal cancer (CRC) burden by timely intervention for high-risk individuals. However, effective risk prediction models are lacking for personalized CRC early screening in East Asian (EAS) population. We aimed to develop, validate, and optimize a comprehensive risk prediction model across all stages of the dynamic adenoma-carcinoma sequence in EAS population. Methods To develop precision risk-stratification and intervention strategies, we developed three trans-ancestry PRSs targeting colorectal neoplasms: (1) using 148 previously identified CRC risk loci (PRS 148 ); (2) SNPs selection from large-scale meta-analysis data by clumping and thresholding (PRS 183 ); (3) PRS-CSx, a Bayesian approach for genome-wide risk prediction (PRS Genomewide ). Then, the performance of each PRS was assessed and validated in two independent cross-sectional screening sets, including 4600 patients with advanced colorectal neoplasm, 4495 patients with non-advanced adenoma, and 21,199 normal individuals from the ZJCRC (Zhejiang colorectal cancer set; EAS) and PLCO (the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; European, EUR) studies. The optimal PRS was further incorporated with lifestyle factors to stratify individual risk and ultimately tested in the PLCO and UK Biobank prospective cohorts, totaling 350,013 participants. Results Three trans-ancestry PRSs achieved moderately improved predictive performance in EAS compared to EUR populations. Remarkably, the PRSs effectively facilitated a thorough risk assessment across all stages of the dynamic adenoma-carcinoma sequence. Among these models, PRS 183 demonstrated the optimal discriminatory ability in both EAS and EUR validation datasets, particularly for individuals at risk of colorectal neoplasms. Using two large-scale and independent prospective cohorts, we further confirmed a significant dose–response effect of PRS 183 on incident colorectal neoplasms. Incorporating PRS 183 with lifestyle factors into a comprehensive strategy improves risk stratification and discriminatory accuracy compared to using PRS or lifestyle factors separately. This comprehensive risk-stratified model shows potential in addressing missed diagnoses in screening tests (best NPV = 0.93), while moderately reducing unnecessary screening (best PPV = 0.32). Conclusions Our comprehensive risk-stratified model in population-based CRC screening trials represents a promising advancement in personalized risk assessment, facilitating tailored CRC screening in the EAS population. This approach enhances the transferability of PRSs across ancestries and thereby helps address health disparity. Graphical Abstract
Safety and efficacy of stent retrievers plus contact aspiration in patients with acute ischaemic anterior circulation stroke and positive susceptibility vessel sign in France (VECTOR): a randomised, single-blind trial
Authors: Romain Bourcier, Gaultier Marnat, Cyril Dargazanli, François Zhu, Arturo Consoli, Eimad Shotar, Kevin Premat, François Eugene, Kevin Janot, Vincent L'Allinec, Julien Ognard, Jean-Philippe Desilles, Raphael Blanc, Jean-Christophe Gentric, Frédéric Bourdain, Julien Labreuche, Liang Liao, Frédéric Clarençon, Xavier Barreau, Héloïse Ifergan, Jean-François Hak, Basile Kerleroux, Raoul Pop, Sébastien Soize, Nicolas Bricout, Jildaz Caroff, Johann Sebastian Richter, Hubert Desal, Bertrand Lapergue, Aymeric Rouchaud
Journal: The Lancet Neurology (2024)
Recent advances in diagnosing, managing, and understanding the pathophysiology of cluster headache
Authors: Anja S Petersen, Nunu Lund, Peter J Goadsby, Andrea C Belin, Shuu-Jiun Wang, Rolf Fronczek, Mark Burish, Soo-Jin Cho, Mario F P Peres, Rigmor H Jensen
Journal: The Lancet Neurology (2024)
Clinical management of liver cyst infections: an international, modified Delphi-based clinical decision framework
Authors: Renée Duijzer, Lucas H P Bernts, Anja Geerts, Bart van Hoek, Minneke J Coenraad, Chantal Rovers, Domenico Alvaro, Ed J Kuijper, Frederik Nevens, Jan Halbritter, Jordi Colmenero, Juozas Kupcinskas, Mahdi Salih, Marie C Hogan, Maxime Ronot, Valerie Vilgrain, Nicolien M Hanemaaijer, Patrick S Kamath, Pavel Strnad, Richard Taubert, Ron T Gansevoort, Roser Torra, Silvio Nadalin, Tatsuya Suwabe, Tom J G Gevers, Vincenzo Cardinale, Joost P H Drenth, Marten A Lantinga
Journal: The Lancet. Gastroenterology & hepatology (2024)
Factors associated with skilled birth attendance in 37 low-income and middle-income countries: a secondary analysis of nationally representative, individual-level data
Authors: Jan Priebe, John Amuasi, Teguh Dartanto, Ghyslain Mombo-Ngoma, Maximilian Guigas
Journal: The Lancet Global Health (2024)

Progress on skilled birth attendance (SBA) has been very uneven across low-income and middle-income countries (LMICs). There is scant empirical evidence on the role of fundamental development processes in explaining differences in SBA outcomes across world regions over time in these settings. We therefore aimed to estimate how these processes have contributed to observed changes in SBA across Latin America and the Caribbean, South Asia, Southeast Asia, and sub-Saharan Africa.
Patients taking benralizumab, dupilumab, or mepolizumab have lower postvaccination SARS-CoV-2 immunity
Authors: Martin C Runnstrom, Pedro A Lamothe, Caterina E Faliti, Narayanaiah Cheedarla, Alberto Moreno, Mehul S Suthar, Rishika Nahata, Mayuran Ravindran, Natalie S Haddad, Andrea Morrison-Porter, Hannah Quehl, Richard P Ramonell, Matthew Woodruff, Fabliha Anam, Rebeca Zhang, Colin Swenson, Carmen Polito, Wendy Neveu, Rahulkumar Patel, Natalia Smirnova, Doan C Nguyen, Caroline Kim, Ian Hentenaar, Shuya Kyu, Sabeena Usman, Thuy Ngo, Zhenxing Guo, Hao Wu, John L Daiss, Jiwon Park, Kelly E Manning, Bursha Wali, Madison L Ellis, Sunita Sharma, Fernando Holguin, Suneethamma Cheedarla, Andrew S Neish, John D Roback, Ignacio Sanz, F Eun-Hyung Lee
Journal: Journal of Allergy and Clinical Immunology (2024)
Diagnostic yield as an important metric for the evaluation of novel tuberculosis tests: rationale and guidance for future research
Authors: Tobias Broger, Florian M Marx, Grant Theron, Ben J Marais, Mark P Nicol, Andrew D Kerkhoff, Ruvandhi Nathavitharana, Helena Huerga, Ankur Gupta-Wright, Mikashmi Kohli, Brooke E Nichols, Monde Muyoyeta, Graeme Meintjes, Morten Ruhwald, Rosanna W Peeling, Nitika Pant Pai, Nira R Pollock, Madhukar Pai, Adithya Cattamanchi, David W Dowdy, Puneet Dewan, Claudia M Denkinger
Journal: The Lancet Global Health (2024)

Better access to tuberculosis testing is a key priority for fighting tuberculosis, the leading cause of infectious disease deaths in people. Despite the roll-out of molecular WHO-recommended rapid diagnostics to replace sputum smear microscopy over the past decade, a large diagnostic gap remains. Of the estimated 10·6 million people who developed tuberculosis globally in 2022, more than 3·1 million were not diagnosed. An exclusive focus on improving tuberculosis test accuracy alone will not be sufficient to close the diagnostic gap for tuberculosis. Diagnostic yield, which we define as the proportion of people in whom a diagnostic test identifies tuberculosis among all people we attempt to test for tuberculosis, is an important metric not adequately explored. Diagnostic yield is particularly relevant for subpopulations unable to produce sputum such as young children, people living with HIV, and people with subclinical tuberculosis. As more accessible non-sputum specimens (eg, urine, oral swabs, saliva, capillary blood, and breath) are being explored for point-of-care tuberculosis testing, the concept of yield will be of growing importance. Using the example of urine lipoarabinomannan testing, we illustrate how even tests with limited sensitivity can diagnose more people with tuberculosis if they enable increased diagnostic yield. Using tongue swab-based molecular tuberculosis testing as another example, we provide definitions and guidance for the design and conduct of pragmatic studies that assess diagnostic yield. Lastly, we show how diagnostic yield and other important test characteristics, such as cost and implementation feasibility, are essential for increased effective population coverage, which is required for optimal clinical care and transmission impact. We are calling for diagnostic yield to be incorporated into tuberculosis test evaluation processes, including the WHO Grading of Recommendations, Assessment, Development, and Evaluations process, providing a crucial real-life implementation metric that complements traditional accuracy measures.
The drug drought in maternal health: an ongoing predicament
Authors: Anne Ammerdorffer, Annie R A McDougall, Andrew Tuttle, Sara Rushwan, Lester Chinery, Joshua P Vogel, Maya Goldstein, A Metin Gülmezoglu
Journal: The Lancet Global Health (2024)

We developed a comprehensive database of medicines that are used or are being investigated for pre-eclampsia or eclampsia, preterm birth or labour, postpartum haemorrhage, intrauterine growth restriction, and fetal distress and that were in active development between 2000 and 2021. A total of 444 candidates were identified: approximately half of candidates were in active development, two-thirds had been repurposed after initially being used for another condition, and just under half were in preclinical studies. Only 64 candidates were in active late-stage (phase 3) development as of Oct 25, 2021, and given the slow pace of biomedical development, it could take years before any of these products eventually make it to market. A lack of innovation for maternal health medicines persists, and the market continues to fail pregnant individuals. There is a need for collective action from all relevant stakeholders to accelerate investment in the development of new or improved medicines for pregnancy-related conditions.
Comparing CHA2DS2-VA and CHA2DS2-VASc scores for stroke risk stratification in patients with atrial fibrillation: a temporal trends analysis from the retrospective Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) cohort
Authors: Konsta Teppo, Gregory Yoke Hong Lip, Kari Eino Juhani Airaksinen, Olli Halminen, Jari Haukka, Jukka Putaala, Pirjo Mustonen, Miika Linna, Juha Hartikainen, Mika Lehto
Journal: The Lancet Regional Health - Europe (2024)

Contemporary data have shown a decrease in the ischaemic stroke risk associated with female sex in patients with atrial fibrillation (AF). We evaluated temporal trends in the predictive value of a non-sex CHA
Implications of food ultra-processing on cardiovascular risk considering plant origin foods: an analysis of the UK Biobank cohort
Authors: Fernanda Rauber, Maria Laura da Costa Louzada, Kiara Chang, Inge Huybrechts, Marc J Gunter, Carlos Augusto Monteiro, Eszter P Vamos, Renata Bertazzi Levy
Journal: The Lancet Regional Health - Europe (2024)
Zoonotic infections by avian influenza virus: changing global epidemiology, investigation, and control
Authors: Mei Kang, Li-Fang Wang, Bo-Wen Sun, Wen-Bo Wan, Xiang Ji, Guy Baele, Yu-Hai Bi, Marc A Suchard, Alexander Lai, Min Zhang, Lin Wang, Yan-Hong Zhu, Lei Ma, Hai-Peng Li, Ayidana Haerheng, Yang-Rui Qi, Rui-Lan Wang, Na He, Shuo Su
Journal: The Lancet Infectious Diseases (2024)
Survival among people with HIV and their families in Denmark 1995–2021: a nationwide population-based cohort study
Authors: Caroline Eves, Lars Haukali Omland, Jan Gerstoft, Gitte Kronborg, Isik Somuncu Johansen, Carsten Schade Larsen, Anders Porskrog, Michael Dalager-Pedersen, Suzanne Lunding, Steffen Leth, Lars Nørregaard Nielsen, Malte Mose Tetens, Niels Obel
Journal: The Lancet Regional Health - Europe (2024)

Survival among people with HIV (PWH) has vastly improved globally over the last few decades but remains lower than among the general population. We aimed to estimate time trends of survival among PWH and their families from 1995 to 2021.
In-hospital mortality, comorbidities, and costs of one million mechanically ventilated patients in Germany: a nationwide observational study before, during, and after the COVID-19 pandemic
Authors: Christian Karagiannidis, Franz Krause, Claas Bentlage, Johannes Wolff, Thomas Bein, Wolfram Windisch, Reinhard Busse
Journal: The Lancet Regional Health - Europe (2024)
Trade-offs between clinical performance and test accessibility in tuberculosis diagnosis: a multi-country modelling approach for target product profile development
Authors: Alexandra de Nooy, Tom Ockhuisen, Alexei Korobitsyn, Shaukat A Khan, Morten Ruhwald, Nazir Ismail, Mikashmi Kohli, Brooke E Nichols
Journal: The Lancet Global Health (2024)

Tuberculosis continues to be a leading cause of infectious disease mortality, and effective screening and diagnosis remains crucial. Despite progress made, diagnostic gaps remain due to poor access to diagnostic tools and testing, particularly in rural and remote areas. As such, the development of target product profiles is essential in guiding the development of new diagnostic tools, however target product profiles often lack evidence-based information and do not consider trade-offs between test accuracy and accessibility.
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study
Authors: Sue Ann Costa Clemens, Brett Jepson, Qasim E Bhorat, Abdullahi Ahmad, Tauseefullah Akhund, Parvinder K Aley, Himanshu Bansal, Sagida Bibi, Elizabeth J Kelly, Mark Khan, Teresa Lambe, Johan J Lombaard, Sam Matthews, Eveline Pipolo Milan, Urban Olsson, Maheshi N Ramasamy, Maria Sanali Moura de Oliveira Paiva, Seth Seegobin, Kathryn Shoemaker, Ameena Szylak, Tonya Villafana, Andrew J Pollard, Justin A Green
Journal: The Lancet Microbe (2024)
Thrombotic risk and features of patients with inferior vena cava agenesis: a multicentre, retrospective, observational study
Authors: Carlos Bravo-Pérez, Ana Blanco, Nuria Revilla, Jorge Cobos, Alba Salgado-Parente, Susana Asenjo, Ramiro Méndez, Luis Marti-Bonmati, Santiago Bonanad, José C Albillos, Nerea Castro, Shally Marcellini, Paul López Sala, Maialen Lasa, José M Bastida, María S Infante, Miguel A Corral, Javier Pagan, Pilar Llamas, Juan J Rodríguez-Sevilla, Agustín Rodríguez-Alen, Teresa S Sevivas, Daniela Morello, Cristina García Villar, Sara Lojo, Ana Marco, Paolo Simioni, Vicente Vicente, María L Lozano, María E de la Morena-Barrio, José M García-Santos, Javier Corral, Carlos Bravo-Perez, Ana Blanco, Nuria Revilla, Jorge Cobos, Alba Salgado-Parente, Susana Asenjo, Ramiro Méndez, Luis Marti-Bonmati, Santiago Bonanad, José C. Albillos, Nerea Castro, Shally Marcellini, Paul López Sala, Maialen Lasa, José M. Bastida, María S. Infante, Miguel A. Corral, Javier Pagan, Pilar Llamas, Juan J. Rodríguez-Sevilla, Agustín Rodríguez-Alen, Teresa S. Sevivas, Daniela Morello, Cristina García Villar, Sara Lojo, Ana Marco, Paolo Simioni, Vicente Vicente, María L. Lozano, María E. de la Morena-Barrio, José M. García-Santos, Javier Corral
Journal: The Lancet Haematology (2024)
Optimal drainage time after evacuation of chronic subdural haematoma (DRAIN TIME 2): a multicentre, randomised, multiarm and multistage non-inferiority trial in Denmark
Authors: Mads Hjortdal Grønhøj, Thorbjørn Søren Rønn Jensen, Rares Miscov, Ann Kathrine Sindby, Birgit Debrabant, Torben Hundsholt, Carsten Reidies Bjarkam, Bo Bergholt, Kåre Fugleholm, Frantz Rom Poulsen
Journal: The Lancet Neurology (2024)
Analysis of opioid analgesics consumption in Africa: a longitudinal study from a 20-year continental perspective
Authors: Yacine Hadjiat, Jallal Toufiq, Christian Ntizimira, Lars Arendt-Nielsen, Benoit Burucoa, Erwan Treillet, Nicolas Authier, Serge Perrot
Journal: The Lancet Global Health (2024)

Opioid analgesics are essential for managing acute and chronic pain in diseases such as cancer. Inadequate opioid access remains a major public health concern in low-income regions including Africa. This study aimed to provide updated and comprehensive data on changes in opioid consumption, specifically in Africa.
Cost-effectiveness of interventions for HIV/AIDS, malaria, syphilis, and tuberculosis in 128 countries: a meta-regression analysis
Authors: Fiona Silke, Lauren Earl, Johnathan Hsu, Mark M Janko, Jonah Joffe, Aishe Memetova, Danielle Michael, Peng Zheng, Aleksandr Aravkin, Christopher J L Murray, Marcia R Weaver
Journal: The Lancet Global Health (2024)

Cost-effectiveness analyses have been conducted for many interventions for HIV/AIDS, malaria, syphilis, and tuberculosis, but they have not been conducted for all interventions that are currently recommended in all countries. To support national decision makers in the effective allocation of resources, we conducted a meta-regression analysis of published incremental cost-effectiveness ratios (ICERs) for interventions for these causes, and predicted ICERs for 14 recommended interventions for Global Fund-eligible countries.
Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries
Authors: Eleana Bolla, Anne Grete Semb, Anne M Kerola, Eirik Ikdahl, Michelle Petri, Guillermo J Pons-Estel, George A Karpouzas, Petros P Sfikakis, Rosana Quintana, Durga Prasanna Misra, Eduardo Ferreira Borba, Ignacio Garcia-de la Torre, Tatiana V Popkova, Bahar Artim-Esen, Anne Troldborg, Hilda Fragoso-Loyo, Sofia Ajeganova, Ayten Yazici, Gustavo Aroca-Martinez, Haner Direskeneli, Manuel F Ugarte-Gil, Marta Mosca, Mohit Goyal, Elisabet Svenungsson, Carla Macieira, Alberta Hoi, Karoline Lerang, Nathalie Costedoat-Chalumeau, Angela Tincani, Erkin Mirrakhimov, Isabel Acosta Colman, Alvaro Danza, Loreto Massardo, Jelena Blagojevic, Neslihan Yılmaz, Dana Tegzová, Sule Yavuz, Cengiz Korkmaz, Eric Hachulla, Mario J Moreno Alvarez, Roberto Muñoz-Louis, Nikos Pantazis, Maria G Tektonidou, Veronica Bellomio, Ilaria Cavazzana, Nikita Khmelinskii, Odirlei Andre Monticielo, Margarita Portela Hernández, Miguel Angel Saavedra Salinas, Marina Scolnik, Ana Carolina Silva Montandon, Esin Yilmaz, Dina Zucchi
Journal: The Lancet Rheumatology (2024)
Global health for rare diseases through primary care
Authors: Gareth Baynam, Adam L Hartman, Mary Catherine V Letinturier, Matt Bolz-Johnson, Prescilla Carrion, Alice Chen Grady, Xinran Dong, Marc Dooms, Lauren Dreyer, Holm Graessner, Alicia Granados, Tudor Groza, Elisa Houwink, Saumya Shekhar Jamuar, Tania Vasquez-Loarte, Biruté Tumiene, Samuel Agyei Wiafe, Heidi Bjornson-Pennell, Stephen Groft
Journal: The Lancet Global Health (2024)

Rare diseases affect over 300 million people worldwide and are gaining recognition as a global health priority. Their inclusion in the UN Sustainable Development Goals, the UN Resolution on Addressing the Challenges of Persons Living with a Rare Disease, and the anticipated WHO Global Network for Rare Diseases and WHO Resolution on Rare Diseases, which is yet to be announced, emphasise their significance. People with rare diseases often face unmet health needs, including access to screening, diagnosis, therapy, and comprehensive health care. These challenges highlight the need for awareness and targeted interventions, including comprehensive education, especially in primary care. The majority of rare disease research, clinical services, and health systems are addressed with specialist care. WHO Member States have committed to focusing on primary health care in both universal health coverage and health-related Sustainable Development Goals. Recognising this opportunity, the International Rare Diseases Research Consortium (IRDiRC) assembled a global, multistakeholder task force to identify key barriers and opportunities for empowering primary health-care providers in addressing rare disease challenges.
Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study
Authors: Vera Golder, Rangi Kandane-Rathnayake, Ning Li, Worawit Louthrenoo, Yi-Hsing Chen, Jiacai Cho, Aisha Lateef, Laniyati Hamijoyo, Shue Fen Luo, Yeong-Jian Wu, Sandra V Navarra, Leonid Zamora, Zhanguo Li, Sargunan Sockalingam, Yasuhiro Katsumata, Masayoshi Harigai, Yanjie Hao, Zhuoli Zhang, Duminda Basnayake, Madelynn Chan, Jun Kikuchi, Tsutomu Takeuchi, Sang-Cheol Bae, Fiona Goldblatt, Shereen Oon, Sean O'Neill, Kristine Ng, Annie Law, Nicola Tugnet, Sunil Kumar, Cherica Tee, Michael Tee, Naoaki Ohkubo, Yoshiya Tanaka, Chak Sing Lau, Alberta Hoi, Mandana Nikpour, Eric F Morand
Journal: The Lancet Rheumatology (2024)
The time of equipoise on the use of biological DMARDs in for inflammatory arthritis during pregnancy is finally over: a reappraisal of evidence to optimise pregnancy management
Authors: Ian Giles, Iona Thorne, Nanna Surlemont Schmidt, Claire Reid, Amy Crossley, Monica Panca, Nick Freemantle, Clare Tower, Shouvik Dass, Shefali K Sharma, David Williams, Sean O'Neill, Radboud J E M Dolhain, Nataša Toplak, Kenneth Hodson, Catherine Nelson-Piercy, Megan E B Clowse
Journal: The Lancet Rheumatology (2024)
Digital in-line holographic microscopy for label-free identification and tracking of biological cells
Authors: Jihwan Kim, Sang Joon Lee
Journal: Military Medical Research (2024)

Abstract Digital in-line holographic microscopy (DIHM) is a non-invasive, real-time, label-free technique that captures three-dimensional (3D) positional, orientational, and morphological information from digital holographic images of living biological cells. Unlike conventional microscopies, the DIHM technique enables precise measurements of dynamic behaviors exhibited by living cells within a 3D volume. This review outlines the fundamental principles and comprehensive digital image processing procedures employed in DIHM-based cell tracking methods. In addition, recent applications of DIHM technique for label-free identification and digital tracking of various motile biological cells, including human blood cells, spermatozoa, diseased cells, and unicellular microorganisms, are thoroughly examined. Leveraging artificial intelligence has significantly enhanced both the speed and accuracy of digital image processing for cell tracking and identification. The quantitative data on cell morphology and dynamics captured by DIHM can effectively elucidate the underlying mechanisms governing various microbial behaviors and contribute to the accumulation of diagnostic databases and the development of clinical treatments.
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial
Authors: Arndt Vogel, Anna Saborowski, Patrick Wenzel, Henning Wege, Gunnar Folprecht, Albrecht Kretzschmar, Philipp Schütt, Lutz Jacobasch, Nicolas Ziegenhagen, Stefan Boeck, Danmei Zhang, Stephan Kanzler, Sebastian Belle, Johannes Mohm, Eray Gökkurt, Christian Lerchenmüller, Ullrich Graeven, Daniel Pink, Thorsten Götze, Martha M Kirstein
Journal: The Lancet. Gastroenterology & hepatology (2024)